Mitochondrial dynamics: cardiolipin, cristae architecture, and mitochondrial-derived peptides

Detailed explanation

Mitochondrial dynamics research targets the structural, energetic, and signalling functions of the mitochondrion — the double-membrane organelle whose progressive dysfunction is a central feature of the cellular ageing phenotype and of many degenerative conditions. Mitochondria are not simple energy-producing organelles but dynamic structures that undergo continuous fission, fusion, and biogenesis, with their cristae architecture (the highly folded inner-membrane invaginations that house the electron-transport chain and ATP synthase) directly determining ATP production capacity and reactive oxygen species (ROS) generation. Loss of cristae organisation — a hallmark of ageing and mitochondrial disease — impairs oxidative phosphorylation efficiency and increases ROS leak, driving the metabolic and redox phenotype of cellular ageing. Cardiolipin is the mitochondrial-signature phospholipid, comprising four fatty acid chains attached to a glycerol scaffold and localised almost exclusively to the inner mitochondrial membrane. It plays essential structural and functional roles: cardiolipin binds and stabilises the respiratory chain complexes I, III, IV, and ATP synthase in higher-order supercomplexes; cardiolipin curvature stress drives cristae membrane folding; cardiolipin binding regulates cytochrome c retention within cristae junctions, preventing inappropriate apoptotic release. Cardiolipin oxidation and pathological remodelling (loss of tetralinoleoyl-cardiolipin, accumulation of monolysocardiolipin) is a documented feature of ageing mitochondria, ischaemia-reperfusion injury, and multiple mitochondrial diseases including Barth syndrome (a genetic tafazzin deficiency that impairs cardiolipin acyl-chain remodelling). SS-31 (elamipretide, formerly Bendavia) is the leading pharmacological compound targeting cardiolipin biology directly. It is a tetrapeptide (D-Arg-2',6'-dimethyl-tyrosine-Lys-Phe-NH₂) that selectively partitions into the inner mitochondrial membrane and binds cardiolipin non-covalently, stabilising cristae architecture and preserving supercomplex organisation during oxidative stress. In pre-clinical and clinical work SS-31 has shown effects on skeletal muscle bioenergetics in primary mitochondrial myopathy, cardiac function in heart failure with preserved ejection fraction, dry age-related macular degeneration, and Barth syndrome — with mixed Phase III results across these indications reflecting both mechanistic complexity and clinical-trial-design challenges. Mitochondrial-derived peptides (MDPs) represent a second, biologically distinct research strategy. These are bioactive peptides encoded by short open reading frames within the mitochondrial genome and translated by mitochondrial ribosomes. The MDP field began with humanin's identification in 2003 (Hashimoto et al., PNAS) as a peptide encoded within the mitochondrial 16S rRNA region with cytoprotective activity against β-amyloid toxicity in neuronal culture. Subsequent MDPs include MOTS-c (2015, encoded in 12S rRNA, described in detail in the metabolic cluster) and the SHLP1-6 family. MDPs act partly through paracrine and endocrine signalling — circulating in plasma to affect distant tissues — connecting cellular energy status to broader physiology through a mitochondrial-nuclear retrograde signalling framework. Humanin's mechanism involves binding of two heterotrimeric receptor complexes (formyl peptide receptor-like 1 FPRL1/FPR2 alongside the ciliary neurotrophic factor receptor CNTFR, gp130, and WSX-1) and inhibition of pro-apoptotic Bax/Bak-mediated mitochondrial outer membrane permeabilisation. Downstream effects include neuroprotection against β-amyloid toxicity (the original discovery context), cardioprotection against ischaemia-reperfusion injury, and improved insulin sensitivity in metabolic models. Circulating humanin plasma concentrations decline with age and are reduced in Alzheimer's disease, type-2 diabetes, and several other age-related conditions. MOTS-c (cross-listed here from the metabolic cluster) activates AMPK signalling through folate-cycle modulation, with downstream effects on fatty acid oxidation, mitochondrial biogenesis, and skeletal-muscle glucose handling. The longevity framing reflects the age-related decline in MOTS-c plasma concentration and the pre-clinical restoration of aged-mouse exercise capacity documented by Reynolds et al. (Nat Commun 2021). Standard pre-clinical assays for mitochondrial-dynamics research include Seahorse extracellular flux analysis for oxygen consumption rate (OCR) and extracellular acidification rate (ECAR); high-resolution respirometry (Oroboros) for respiratory-chain-complex-specific assessment; mitochondrial membrane potential measurement using TMRM or JC-1 fluorescent probes; electron microscopy for cristae structure quantification; and molecular readouts including PGC-1α expression, mtDNA copy number, and cardiolipin lipidomics. Cellular-ageing readouts include senescence-associated β-galactosidase staining, senescence-associated secretory phenotype (SASP) cytokines, and mitochondrial-membrane-potential decline in aged versus young cells. The mitochondrial-dynamics cluster overlaps mechanistically with the metabolic cluster (through AMPK, insulin sensitivity, and adipose-tissue effects) and with the longevity framing more broadly. It represents a coherent research pharmacological space with growing clinical-development attention as the mitochondrial dysfunction framework of ageing becomes better validated.